Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Successful translation and future prospects of TALEN editing for leukemia patients.

Werner Sunderland M, Peggs KS.

Expert Opin Biol Ther. 2018 Jul;18(7):725-726. doi: 10.1080/14712598.2018.1484105. Epub 2018 Jun 14. No abstract available.

PMID:
29860877
2.

The function and dysfunction of memory CD8+ T cells in tumor immunity.

Reading JL, Gálvez-Cancino F, Swanton C, Lladser A, Peggs KS, Quezada SA.

Immunol Rev. 2018 May;283(1):194-212. doi: 10.1111/imr.12657. Review.

PMID:
29664561
3.

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

Peggs KS.

Blood Adv. 2018 Apr 10;2(7):817-820. doi: 10.1182/bloodadvances.2017011122. No abstract available.

4.

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA.

Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22.

5.

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A.

Br J Haematol. 2018 Apr;181(1):86-96. doi: 10.1111/bjh.15152. Epub 2018 Feb 22.

PMID:
29468647
6.

Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.

Ghorani E, Rosenthal R, McGranahan N, Reading JL, Lynch M, Peggs KS, Swanton C, Quezada SA.

Ann Oncol. 2018 Jan 1;29(1):271-279. doi: 10.1093/annonc/mdx687.

7.

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.

Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, Finke J, Poiré X, Maillard N, Milpied N, Yakoub-Agha I, Koh M, Kröger N, Nagler A, Koc Y, Dietrich S, Montoto S, Dreger P.

Bone Marrow Transplant. 2018 May;53(5):617-624. doi: 10.1038/s41409-017-0067-3. Epub 2018 Jan 15.

PMID:
29335632
8.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
9.

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA.

Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.

PMID:
29131157
10.

The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.

Joshi K, Chain BM, Peggs KS, Quezada SA.

Cold Spring Harb Perspect Med. 2018 Jan 2;8(1). pii: a027086. doi: 10.1101/cshperspect.a027086. Review.

PMID:
28630228
11.

Immunotherapy for transplantation-associated viral infections.

Roddie C, Peggs KS.

J Clin Invest. 2017 Jun 30;127(7):2513-2522. doi: 10.1172/JCI90599. Epub 2017 Jun 19. Review.

12.

Evolving adoptive cellular therapies in urological malignancies.

Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M.

Lancet Oncol. 2017 Jun;18(6):e341-e353. doi: 10.1016/S1470-2045(17)30327-3. Review.

PMID:
28593860
13.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

14.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA.

Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.

15.

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.

Green K, Pearce K, Sellar RS, Jardine L, Nicolson PLR, Nagra S, Bigley V, Jackson G, Dickinson AM, Thomson K, Mackinnon S, Craddock C, Peggs KS, Collin M.

Biol Blood Marrow Transplant. 2017 May;23(5):805-812. doi: 10.1016/j.bbmt.2017.02.007. Epub 2017 Feb 14.

16.

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaaj2013. doi: 10.1126/scitranslmed.aaj2013. Erratum in: Sci Transl Med. 2017 Feb 15;9(377):null.

PMID:
28123068
17.

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.

Radford J, McKay P, Malladi R, Johnson R, Bloor A, Percival F, Sureda A, Peggs KS.

Bone Marrow Transplant. 2017 Mar;52(3):452-454. doi: 10.1038/bmt.2016.244. Epub 2017 Jan 16. No abstract available.

18.

Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?

Furness AJ, Quezada SA, Peggs KS.

Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064. No abstract available.

19.

A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.

Kothari J, Foley M, Peggs KS, Mackenzie S, Thomson K, Morris E, Ardeshna KM, Virchis AE, Linch DC, Lambert J.

Bone Marrow Transplant. 2016 Oct;51(10):1397-1399. doi: 10.1038/bmt.2016.134. Epub 2016 May 23. No abstract available.

PMID:
27214072
20.

TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.

Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule M, Hererro J, Peggs KS, Quezada SA.

Cancer Res. 2016 Apr 15;76(8):2087-93. doi: 10.1158/0008-5472.CAN-15-3352. Erratum in: Cancer Res. 2017 Jun 15;77(12 ):3379. Cancer Res. 2016 Oct 15;76(20):6130.

21.

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

Reyal Y, Kayani I, Bloor AJC, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Ben Taylor M, Bishton MJ, Morris EC, Thomson KJ, Russell N, Mackinnon S, Peggs KS.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.

22.

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C.

Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.

23.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation.

Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Webster AP, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SG, Madrigal JA, Rakyan VK, Peggs KS, Beck S.

Genome Med. 2015 Dec 15;7:128. doi: 10.1186/s13073-015-0246-z.

24.

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Śledzińska A, Menger L, Bergerhoff K, Peggs KS, Quezada SA.

Mol Oncol. 2015 Dec;9(10):1936-65. doi: 10.1016/j.molonc.2015.10.008. Epub 2015 Oct 26. Review.

25.

Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.

Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, Wynn R, Vora A, Mackinnon S, Peggs KS, Crawley C, Craddock C, Pagliuca A, Cook G, Snowden JA, Clark A, Marsh J, Querol S, Parkes G, Braund H, Rocha V.

Br J Haematol. 2016 Feb;172(3):360-70. doi: 10.1111/bjh.13802. Epub 2015 Nov 18.

PMID:
26577457
26.

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells.

Menger L, Gouble A, Marzolini MA, Pachnio A, Bergerhoff K, Henry JY, Smith J, Pule M, Moss P, Riddell SR, Quezada SA, Peggs KS.

Blood. 2015 Dec 24;126(26):2781-9. doi: 10.1182/blood-2015-08-664755. Epub 2015 Oct 27.

27.

Recent advances in antibody-based therapies for Hodgkin Lymphoma.

Peggs KS.

Br J Haematol. 2015 Oct;171(2):171-178. doi: 10.1111/bjh.13578. Epub 2015 Jul 17. Review.

PMID:
26184792
28.

Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma.

Gohil SH, Ardeshna KM, Lambert JM, Pule MA, Mohamedbhai S, Virchis A, Morris EC, Linch DC, Thomson KJ, Peggs KS.

Br J Haematol. 2015 Oct;171(2):197-204. doi: 10.1111/bjh.13561. Epub 2015 Jun 26.

PMID:
26119524
29.

Antifungal stewardship: towards defining safe stopping criteria for therapeutic oral azoles.

Marzolini MA, Thomson KJ, Peggs KS.

Br J Haematol. 2016 Jan;172(2):285-7. doi: 10.1111/bjh.13474. Epub 2015 May 5. No abstract available.

PMID:
25939287
30.

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.

Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J.

Cancer Immunol Immunother. 2015 Jun;64(6):765-7. doi: 10.1007/s00262-015-1689-1. Epub 2015 Apr 1.

PMID:
25828465
31.

Cytomegalovirus-specific T-cell therapies: current status and future prospects.

Nicholson E, Peggs KS.

Immunotherapy. 2015;7(2):135-46. doi: 10.2217/imt.14.99. Review.

PMID:
25713989
32.

Reprint of: Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.

Boeckh M, Murphy WJ, Peggs KS.

Biol Blood Marrow Transplant. 2015 Feb;21(2 Suppl):S19-24. doi: 10.1016/j.bbmt.2014.12.034. Review.

33.

Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing.

Naccache SN, Peggs KS, Mattes FM, Phadke R, Garson JA, Grant P, Samayoa E, Federman S, Miller S, Lunn MP, Gant V, Chiu CY.

Clin Infect Dis. 2015 Mar 15;60(6):919-23. doi: 10.1093/cid/ciu912. Epub 2015 Jan 7.

34.

CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status.

Sellar RS, Vargas FA, Henry JY, Verfuerth S, Charrot S, Beaton B, Chakraverty R, Quezada SA, Mackinnon S, Thomson KJ, Peggs KS.

Blood. 2015 Jan 22;125(4):731-9. doi: 10.1182/blood-2014-07-589150. Epub 2014 Dec 12.

35.

Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.

Boeckh M, Murphy WJ, Peggs KS.

Biol Blood Marrow Transplant. 2015 Jan;21(1):24-9. doi: 10.1016/j.bbmt.2014.11.002. Epub 2014 Nov 11. Review.

36.

An antitumor boost to TH9 cells.

Quezada SA, Peggs KS.

Nat Immunol. 2014 Aug;15(8):703-5. doi: 10.1038/ni.2945. No abstract available.

PMID:
25045872
37.

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, Marin V, Marafioti T, Chakraverty R, Linch D, Quezada SA, Peggs KS, Pule M.

Blood. 2014 Aug 21;124(8):1277-87. doi: 10.1182/blood-2014-01-545020. Epub 2014 Jun 26.

38.

Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.

Furness AJ, Vargas FA, Peggs KS, Quezada SA.

Trends Immunol. 2014 Jul;35(7):290-8. doi: 10.1016/j.it.2014.05.002. Epub 2014 Jun 18. Review.

PMID:
24953012
39.

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.

Sellar RS, Peggs KS.

Expert Opin Biol Ther. 2014 Aug;14(8):1121-6. doi: 10.1517/14712598.2014.908847. Epub 2014 Apr 25. Review.

PMID:
24762099
40.

Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.

Kothari J, Peggs KS, Bird A, Thomson KJ, Morris E, Virchis AE, Lambert J, Goldstone AH, Linch DC, Ardeshna KM.

Br J Haematol. 2014 May;165(3):334-40. doi: 10.1111/bjh.12741. Epub 2014 Jan 18.

PMID:
24438080
41.

Emerging options for the treatment of melanoma - focus on ipilimumab.

Roddie C, Peggs KS.

Immunotargets Ther. 2014 Mar 17;3:67-78. doi: 10.2147/ITT.S43522. eCollection 2014. Review.

42.

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, Shaw BE, Byrne JL, Brookes C, Craddock CF, Chaganti S.

Bone Marrow Transplant. 2014 Feb;49(2):280-6. doi: 10.1038/bmt.2013.170. Epub 2013 Nov 11.

PMID:
24212561
43.

Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.

Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, Hamm D, Robins HS, Pickering L, Gore M, Nicol DL, Larkin J, Swanton C.

J Pathol. 2013 Dec;231(4):424-32. doi: 10.1002/path.4284.

44.

Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.

Collins GP, Parker AN, Pocock C, Kayani I, Sureda A, Illidge T, Ardeshna K, Linch DC, Peggs KS; British Committee for Standards in Haematology; British Society of Blood and Marrow Transplantation.

Br J Haematol. 2014 Jan;164(1):39-52. doi: 10.1111/bjh.12582. Epub 2013 Oct 1. No abstract available.

PMID:
24117159
45.

Attack of the T-cell clones.

Peggs KS.

Blood. 2013 Sep 12;122(11):1847-8. doi: 10.1182/blood-2013-07-511022. No abstract available.

46.

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA.

J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130579. Epub 2013 Jul 29.

47.

Allogeneic transplantation in the UK: an aggregation of marginal gains?

Thomson KJ, Peggs KS.

Br J Haematol. 2013 Oct;163(2):149-59. doi: 10.1111/bjh.12497. Epub 2013 Jul 27. Review.

PMID:
23889234
48.

Tumour heterogeneity and immune-modulation.

Jamal-Hanjani M, Thanopoulou E, Peggs KS, Quezada SA, Swanton C.

Curr Opin Pharmacol. 2013 Aug;13(4):497-503. doi: 10.1016/j.coph.2013.04.006. Epub 2013 May 7. Review.

49.

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.

Quezada SA, Peggs KS.

Br J Cancer. 2013 Apr 30;108(8):1560-5. doi: 10.1038/bjc.2013.117. Epub 2013 Mar 19.

50.

Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning.

Townsend WM, Holroyd A, Pearce R, Mackinnon S, Naik P, Goldstone AH, Linch DC, Peggs KS, Thomson KJ, Singer M, Howell DC, Morris EC.

Br J Haematol. 2013 May;161(4):578-86. doi: 10.1111/bjh.12294. Epub 2013 Mar 18.

Supplemental Content

Loading ...
Support Center